Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00220077|
Recruitment Status : Unknown
Verified November 2015 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : November 25, 2015
|Condition or disease||Intervention/treatment||Phase|
|Oesophageal Cancer||Procedure: Endoscopy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer|
|Study Start Date :||June 2002|
- To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.
- Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220077
|Contact: Sheela Rao||0208 642 email@example.com|
|Contact: Naureen Starling||0208 642 firstname.lastname@example.org|
|Royal Marsden Hospital||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Contact: Sheela Rao 0208 642 6011 email@example.com|
|Contact: Naureen Starling 0208 642 6011 firstname.lastname@example.org|
|Principal Investigator: David Cunningham|
|Principal Investigator:||David Cunningham||Royal Marsden NHS Foundation Trust|